Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY26 results · Apr–Jun 2025
Suven Life Sciences reported revenue from operations of ₹1.87 crore (up 85.6% from Q1 FY25) and net loss of ₹51.52 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.87 | 1.01 | +85.6% | 1.47 | +27.2% |
| Other income | 0.60 | 4.01 | −85.0% | 1.22 | −50.9% |
| Total income | 2.47 | 5.01 | −50.8% | 2.69 | −8.3% |
| Profit before tax | (51.52) | (28.04) | Loss widened | (43.94) | Loss widened |
| Net profit for the period | (51.52) | (28.04) | Loss widened | (43.94) | Loss widened |
| EPS, basic (₹) | (2.36) | (1.29) | Loss widened | (2.02) | Loss widened |
| Net margin (%) | -2759.8 | -2787.2 | -2995.6 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.87 | 1.01 | +85.6% | 1.47 | +27.2% |
| Other income | 0.59 | 3.93 | −85.0% | 1.19 | −50.5% |
| Total income | 2.46 | 4.94 | −50.3% | 2.66 | −7.6% |
| Profit before tax | (14.78) | (7.67) | Loss widened | (15.07) | Loss narrowed |
| Net profit for the period | (14.78) | (7.67) | Loss widened | (15.07) | Loss narrowed |
| EPS, basic (₹) | (0.68) | (0.35) | Loss widened | (0.69) | Loss narrowed |
| Net margin (%) | -791.7 | -762.0 | -1027.3 |
Consolidated
- Filed with BSE
- 13 Aug 2025, 17:20 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2025, 17:20 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE